TrialThe oncologist2022

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma.

Yang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.